TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, Wilms tumor or other primary renal tumor (including clear cell and rhabdoid)~* Age ≤ 21 years;~* Must be capable of treatment without general anesthesia~* Lesion size 8 mm - 3 cm~* Subjects who have lesions within 2 cm of central structures, will be eligible on a case by-case basis~* Pulmonary metastases found at relapse (does not have to be first relapse); no more than 3 lesions per hemi-thorax will be treated but other lesions in the lung may be present~* Greater than 5 weeks from doxorubicin at the time of consent, with radiation to be initiated no less than 6 weeks from doxorubicin~* Informed consent/assent~* Life expectancy \>3 months~* Pulmonary Function FEV1 ≥ 50% of predicted;~* Concurrent immunotherapy is allowed~Exclusion Criteria:~* Prior whole-lung or hemi-thorax irradiation of greater than 12 Gy received less than 6 months prior to consent (focal radiotherapy to the thorax is not an exclusion)~* Lesion larger than 3 cm in diameter~* Patients for whom surgery would be deemed appropriate rather than radiotherapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 Dose Level 1 [Phase I] (Type: EXPERIMENTAL): Participants with Wilms tumors or other primary renal tumors. Stereotactic Body Radiotherapy (SBRT) Dose Levels for each target lesion are three 8 Gy fractions for 24 Gy total.
- Cohort 1 Dose Level 2 [Phase I] (Type: EXPERIMENTAL): Participants with Wilms tumors or other primary renal tumors. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
- Cohort 1 Dose Level 3 [Phase I] (Type: EXPERIMENTAL): Participants with Wilms tumors or other primary renal tumors. SBRT Dose Levels for each target lesion are three 12 Gy fractions for 36 Gy total.
- Cohort 2 Dose Level 2 [Phase I] (Type: EXPERIMENTAL): Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
- Cohort 2 Dose Level 3 [Phase I] (Type: EXPERIMENTAL): Participants with Ewing sarcoma or rhabdomyosarcoma.SBRT Dose Levels for each target lesion are three 12 Gy fractions for 36 Gy total.
- Cohort 2 Dose Level 2 [Phase II] (Type: EXPERIMENTAL): Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects have fully understood the possible risks and benefits of participating in this study, are willing to follow and able to complete all trial procedures, and have signed informed consent;~2. Age 18-75 years;~3. Patients diagnosed as advanced hepatocellular carcinoma (HCC) histopathologically or cytologically; Progression or intolerance after previous standard systemic therapy;~4. GPC3 is detected positive by immunohistochemistry (IHC);~5. Child-Pugh score ≤ 7;~6. At least one assessable tumor lesion;~7. ECOG score: 0-1;~8. Expected survival ≥ 3 months;~9. Clinical laboratory values meet screening visit criteria~Exclusion Criteria:~1. Previous CAR-T cell, TCR-T cell or other cell therapies or therapeutic tumor vaccination directed at any target;~2. Any previous GPC3 targeted therapy;~3. Prior antitumor therapy with insufficient washout period;~4. Brain metastases with central nervous system symptoms;~5. Pregnant or lactating women~6. HCV-Ab or/and HIV-Ab positive; active syphilis;~7. Severe underlying diseases~8. Any condition that, in the opinion of the investigator, will make the subject unsuitable for participation in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- GPC3 Targeting CART Cells (Type: EXPERIMENTAL): Each subject will receive GPC3 Targeting CART cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a moderate renal insufficiency defined by a creatinine clearance between 30 to 50 ml/min (Cockcroft and Gault formulae) or a severe renal insufficiency (between 15 to 29 ml/min)~* Patients with acute objectively confirmed symptomatic proximal deep-vein thrombosis (DVT) or pulmonary embolism (PE) (with or without deep-vein thrombosis), planned to be treated for at least 3 months~* Patients \>18 years~* Life expectancy more than 3 months~* Social security affiliation~* Signed informed consent~Exclusion Criteria:~* Indication for anticoagulants other than VTE~* Active bleeding or a high risk of bleeding contraindicating anticoagulant treatment; a systolic blood pressure of more than 180 mm Hg or a diastolic blood pressure of more than 110 mm Hg~* Anticoagulation for more than 72 hours prior to randomization~* Chronic liver disease or chronic hepatitis~* Patient at high risk of bleeding~* Creatinine clearance \<15 ml/min or end stage renal disease or indication for extra-renal dialysis~* Need for concomitant anti-platelet therapy other than aspirin 75-325 mg per day. However concomitant treatment with aspirin is discouraged in this population at bleeding risk.~* Concomitant use of a strong inhibitor of cytochrome P-450 3A4 (CYP3A4) (e.g., a protease inhibitor for human immunodeficiency virus infection or azole-antimycotics agents ketoconazole, itraconazole, voriconazole, posaconazole) or a CYP3A4 inducer (e.g., rifampin, carbamazepine, or phenytoin),~* Active pregnancy or expected pregnancy or no effective contraception~* Any contraindication listed in the local labeling of UFH, LMWH or VKA or oral anticoagulant.~* Cancer-associated VTE requiring long-term treatment with LMWH~* Life expectancy of less than 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DOA : Direct Oral Anticoagulants (Type: EXPERIMENTAL): The experimental group receiving DOA regimens: patients will be secondarily randomly assigned within DOAs group between:~* Apixaban (Eliquis® tablet) 10 mg bid for 7 days then 2.5 mg bid for 3 months~* Rivaroxaban (Xarelto® tablet) 15 mg bid for 21 days then 15 mg od for 3 months.
- SOC : Standard Of Care (Type: ACTIVE_COMPARATOR): The control group receiving the standard of care (SOC), i.e. heparins/VKA regimen. Patients will receive the current recommended therapy: subcutaneous or intravenous UFH/VKA in case of severe renal insufficiency and subcutaneous LMWH/VKA in case of moderate renal insufficiency for at least 5 days. VKA will begin concomitantly and continue for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key inclusion criteria:~* Histologically confirmed NSCLC stage IB-IIIA (per AJCC 8th edition), deemed suitable for primary resection by treating surgeon, except for N2 and T4 tumors.~* Subject must have been eligible for surgery and with a planned surgical resection in approximately 4-6 weeks (after the first dose of study treatment).~* A mandatory newly obtained tissue biopsy from primary site was required for study enrollment. An archival biopsy was also acceptable if obtained up to 5 months before first day of study treatment and if the subject did not go through antineoplastic systemic therapies between biopsy collection date and beginning of study treatment.~* Eastern Cooperative oncology group (ECOG) performance status of 0 or 1.~Key exclusion criteria:~* Subjects with unresectable or metastatic disease.~* History of severe hypersensitivity reactions to monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction~* Subjects who received prior systemic therapy (including chemotherapy, other anti-cancer therapies and any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) in the past 3 years before screening~* Active autoimmune disease that has required systemic treatment in the past 2 years prior to randomization. Control of the disorder with replacement therapy was permitted~* Subject with suspected or proven immunocompromised state or infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Canakinumab monotherapy (Type: EXPERIMENTAL): Participants received 200 mg of canakinumab once every 3 weeks for a maximum duration of 6 weeks prior to surgery
- Canakinumab + pembrolizumab (Type: EXPERIMENTAL): Participants received 200 mg of canakinumab in combination with 200 mg of pembrolizumab once every 3 weeks for a maximum duration of 6 weeks prior to surgery
- Pembrolizumab monotherapy (Type: EXPERIMENTAL): Participants received 200 mg of pembrolizumab every 3 weeks for a maximum duration of 6 weeks prior to surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome (PCOS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 18-45, , 8 menstrual cycles annually, elevated serum free testosterone, normal thyroid function test and serum prolactin, exclusion of late onset adrenal hyperplasia~Exclusion Criteria:~* Diabetes mellitus, pulmonary, cardiac, renal, hepatic, cholestatic, neurologic, psychiatric, infectious, malignant diseases,history of breast cancer, history of Deep Vein Thrombosis, pregnancy and lactation.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo tablet and birth control pill daily
- 2 (Type: ACTIVE_COMPARATOR): metformin 2000 mg and birth control pill daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D Supplementation as Non-toxic Immunomodulation in Children With Crohn's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of mild to moderate Crohn's disease~* 8 to 18 years old, inclusive~Exclusion Criteria:~* Children less than 8 years or greater than 18 years at the time of study screening~* Patients with a documented history of hypercalcemia, renal insufficiency, or nephrolithiasis~* Patients taking cholestyramine~* Patients who have a GI tract in discontinuity (ostomy)~* Patients who have serum 25-OH vitamin D levels of \>50 ng/mL at the time of study screening

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Children with Crohn's disease less than 35 kg (Type: ACTIVE_COMPARATOR): These are children ages 8 to 18 years inclusive, with mild to moderately active Crohn's disease.
- Children with Crohn's disease 35 kg or greater (Type: ACTIVE_COMPARATOR): These are children ages 8 to 18 years inclusive, with mild to moderately active Crohn's disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Aged 18-75 years~Histologically or cytologically confirmed extensive-stage disease small cell lung cancer (ED SCLC)~Ongoing clinical benefit (partial response \[PR\], or complete response \[CR\] per RECIST version 1.1) following completion of 4 cycles of first-line platinum-based therapy (cisplatin or carboplatin, plus etoposide)~Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~Subjects must have adequate bone marrow, renal and hepatic function~Exclusion Criteria:~Subjects with Central Nervous System (CNS) metastases~Subjects receiving consolidative chest radiation after last dose of first-line chemotherapy.~Subjects with pleural effusions that cannot be controlled with appropriate interventions.~All side effects attributed to prior anti-cancer therapy must have resolved to Grade 1 or baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ZL-2306(nirapairb) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~1. Written informed consent prior to participation~2. Female and male patients = 40 years of age~3. Patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD) and requiring long-acting dual bronchodilation (LAMA + LABA) treatment according to approved Spiolto® Respimat® SmPC and COPD GOLD guideline recommendation~Exclusion criteria:~1. Patients with contraindications according to Spiolto® Respimat® SmPC~2. Patients who have been treated with a Long-acting beta2 adrenoceptor agonist\\Long-acting muscarinic antagonist (LABA/LAMA) combination (free and fixed dose) in the previous 6 weeks.~3. Patients continuing Long-acting beta2 adrenoceptor agonist Inhalative Corticosteroids (LABA-iCS) treatment should not be additionally treated with Spiolto® Respimat® in order to avoid a double dosing of long-acting beta-agonists~4. Patients for whom further follow-up is not possible at the enrolling site during the planned study period of approx. 6 weeks~5. Pregnancy and lactation~6. Patients currently listed for lung transplantation~7. Current participation in any clinical trial or any other non-interventional study of a drug or device Further exclusion criteria apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Spiolto Respimat (Type: None): COPD patients requiring a fixed combination therapy of two long-acting bronchodilators (LAMA + LABA) according to approved Summary of Product Characteristics (SmPC) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: WP02 Continued Access Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is 18 years of age or greater~* Subject is registered as an active recipient on the UNOS waiting list for liver transplantation~* Subject, or legally authorized representative, is able and willing to give informed consent and HIPAA authorization~* Subject is able and willing to comply with all study requirements~Exclusion Criteria:~* Subject requiring all of the following at the time of transplantation:~  1. Oxygen therapy via a ventilator/respirator~ 2. Inotropic support~ 3. Renal replacement therapy~* Subject has acute/fulminant liver failure (UNOS status 1A)~* Subject undergoing simultaneous transplantation of more than one organ (e.g., liver and kidney)~* Subject is pregnant (as confirmed by urine or serum pregnancy test) or nursing~* Concurrent enrollment in another clinical trial. Subjects enrolled in clinical trials or registries where only measurements and/or samples are taken (NO TEST DEVICE or TEST DRUG USED) are allowed to participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Normothermic Machine Perfusion (NMP) (Type: EXPERIMENTAL): Following the routine retrieval procedure of the liver, it will be placed on the OrganOx metra for Normothermic Machine Perfusion (NMP) for transport per the Investigational Plan and the Instructions for Use.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: NANOS Neck Preserving Hip Stem

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Inclusion criteria:~* Patient requires Primary total hip replacement (THR) to the affected side, unilateral or bilateral. Bilateral only if \>3 months after the first THR~* Patient agreed to participate in the MCO study by signing the Informed Consent form.~* Age of patient at date of surgery 18 to 65 years~* Patient is likely to comply with study follow-up requirements~Exclusion criteria:~* Previously failed endoprosthesis and /or THR components in relevant hip~* Patient has proven osteoporosis~* Pronounced coxa valga with a femoral neck angle \> 145º~* Pronounced coxa vara with a femoral neck angle \< 125º~* History of infection in the affected joint; systemic infections~* Grossly insufficient femoral or acetabular bone stock in the involved hip where a revision cup is indicated~* Spinal disease with neurologic movement disorders~* Alcoholism or addictive disorders~* ASA score is 3 or 4~* Body mass index (BMI) \> 30~* Patient is pregnant or being pregnant during follow up intervals~* Patients understanding of the language is insufficient for understanding the Patient Information and Consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Mechanical Stimulation on Pain Level and Functional Discomfort After Breast Cancer Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Patient who had total mastectomy for a breast cancer or pre-cancerous lesions~* Associated with axillary dissection or removal of the sentinel lymph nodes~* Presenting with functional discomfort and/or pain at the control consultation, 3 weeks after the mastectomy and justifying the prescription of physiotherapy~* Possibility to be treated by a physiotherapist who can carry out both techniques and accepts to perform either one of the techniques according to the randomized allocation of the treatment~* Patient covered by the French social security regime~* Signed and informed consent~Exclusion Criteria:~* Immediate breast reconstruction~* Total bilateral mastectomy~* Contraindication to mechanical stimulation technique~* Patient who are planning to move houses in the next 6 months~* Patients under guardianship

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A - Mechanical Stimulation (Type: EXPERIMENTAL): Patients in this arm will receive, in addition to standard rehabilitation physiotherapy, mechanical stimulation
- Arm B - Massages (Type: SHAM_COMPARATOR): Patients in this arm will receive, in addition to standard rehabilitation physiotherapy, massages.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues